32 results
424B4
OCUP
Ocuphire Pharma Inc
17 Feb 21
Prospectus supplement with pricing info
7:14am
and expansion, which could disrupt its operations.
The COVID-19 pandemic has and could continue to adversely impact Ocuphire’s business, including pre-clinical … a clinical trial at a prospective trial site including due to the ongoing COVID-19 pandemic or other public health emergency;
government or regulatory
424B5
OCUP
Ocuphire Pharma Inc
7 Jun 21
Prospectus supplement for primary offering
4:21pm
in control of the company or changes in our management, which may depress the price of our common stock;
The coronavirus pandemic may have an adverse … in managing this development and expansion, which could disrupt its operations.
The COVID-19 pandemic has and could continue to adversely impact Ocuphire’s
424B5
7y1jryht
11 Mar 21
Prospectus supplement for primary offering
9:19am
424B5
7m6yn68xg3mjgmsdqphd
14 Aug 23
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
tuma8968ziauypn c6e
11 Mar 21
Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update
9:12am
S-4
hyjyf3o1ku artj3
6 Jul 20
Registration of securities issued in business combination transactions
4:08pm
S-4/A
xw9ob1zp7nhtb7tshfv
27 Aug 20
Registration of securities issued in business combination transactions (amended)
5:04pm
424B3
uxcs5
2 Oct 20
Prospectus supplement
9:25am
424B3
xpr5q0r nuo6wp
16 Feb 24
Prospectus supplement
4:31pm